Imbria Pharmaceuticals
Small-molecule therapeutics targeting cardiac energy metabolism pathways to treat cardiovascular diseases
- Sector
- Biotech
- Headquarters
- BOSTON, MA
- Founded
- 2018
- Latest Form D
- $59.2M, Apr 2025
- Total capital
- $140M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $140M
- 3 Form D · last Apr 2025
- 19 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 19
- 21 pending · first 2022
- Rank in peer group#77 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 3rd filing$59.2M
- Private capital raisedForm D · SEC · 2nd filing$40.7M
- Private capital raisedForm D · SEC · 1st filing$40.2M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#77 · top 5%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Andrew LevinResearcherDirectorLinked by 2 patents
- Alvin ShihDirectorNamed in SEC Form D filings
- Charles DunnDirectorNamed in SEC Form D filings
- David-Alexandre C. GrosExecutive Officer, DirectorNamed in SEC Form D filings
- James C. JanuzziDirectorNamed in SEC Form D filings
- Ken HorneDirectorNamed in SEC Form D filings
Show all 12 people
- Komal JoshiExecutive OfficerNamed in SEC Form D filings
- Luse RebeccaDirectorNamed in SEC Form D filings
- Pavan CheruvuDirectorNamed in SEC Form D filings
- Pieter C. BoelhouwerDirectorNamed in SEC Form D filings
- Rebecca LuseDirectorNamed in SEC Form D filings
- Zina Affas BesseDirectorNamed in SEC Form D filings
What it has protected
USPTO · 19 granted of 40- PendingCrystal Forms Of 2-[4-[(2,3,4-TRIMETHOXYPHENYL)METHYL]PIPERAZIN-1-YL]ETHYLPYRIDINE-3-CARBOXYLATEUSPTOApplication 19671774
- GrantedCrystal Forms Of 2-[4-[(2,3,4-TRIMETHOXYPHENYL)METHYL]PIPERAZIN-1-YL]ETHYL PYRIDINE-3-CARBOXYLATEUSPTOUS 12,649,720
- PendingMethods Of Treating Heart Failure With Preserved Ejection Fraction Using Modified Forms Of TrimetazidineUSPTOApplication 19401672
Show all 40 patent records
- Crystal Forms Of 2-[4-[(2,3,4-TRIMETHOXYPHENYL)METHYL]PIPERAZIN-1-YL]ETHYLPYRIDINE-3-CARBOXYLATESep 10, 2026 · Application 19671774Pending
- Crystal Forms Of 2-[4-[(2,3,4-TRIMETHOXYPHENYL)METHYL]PIPERAZIN-1-YL]ETHYL PYRIDINE-3-CARBOXYLATEJun 9, 2026 · US 12,649,720Granted
- Methods Of Treating Heart Failure With Preserved Ejection Fraction Using Modified Forms Of TrimetazidineMar 19, 2026 · Application 19401672Pending
- Methods Of Treating Fibrosis Using Compounds That Promote Glucose OxidationMar 10, 2026 · US 12,569,480Granted
- Methods Of Treating Rheumatic Diseases Using Trimetazidine-based CompoundsMar 5, 2026 · Application 19197314Pending
- Methods Of Treating Heart Failure With Preserved Ejection Fraction Using Modified Forms Of TrimetazidineDec 23, 2025 · US 12,502,389Granted
- Compounds And Methods For Increasing Efficiency Of Cardiac MetabolismNov 6, 2025 · Application 18868353Pending
- Compositions And Methods For Increasing Efficiency Of Cardiac MetabolismAug 21, 2025 · Application 19196944Pending
- Methods For Treating Cardiovascular Conditions And Methods Of Increasing The Efficiency Of Cardiac MetabolismJul 24, 2025 · Application 18703512Pending
- Methods Of Treating Kidney Conditions Using Modified Forms Of TrimetazidineJul 10, 2025 · Application 19090735Pending
- Compositions And Methods For Increasing Efficiency Of Cardiac MetabolismJun 3, 2025 · US 12,318,453Granted
- Methods Of Treating Rheumatic Diseases Using Trimetazidine-based CompoundsJun 3, 2025 · US 12,318,382Granted
- Methods Of Treating Non-obstructive Hypertrophic Cardiomyopathy Using Modified Forms Of TrimetazidineMay 15, 2025 · Application 19027531Pending
- Methods Of Treating Kidney Conditions Using Modified Forms Of TrimetazidineApr 29, 2025 · US 12,285,428Granted
- Methods Of Treating Non-obstructive Hypertrophic Cardiomyopathy Using Modified Forms Of TrimetazidineFeb 25, 2025 · US 12,233,058Granted
- Methods Of Synthesizing 2-[4-[(2,3,4-TRIMETHOXYPHENYL)METHYL] PIPERAZIN-1-YL]ETHYL PYRIDINE-3-CARBOXYLATENov 21, 2024 · Application 18783819Pending
- Methods Of Treating Heart Failure With Hibernating Myocardium Using Modified Forms Of TrimetazidineNov 14, 2024 · Application 18780727Pending
- Methods Of Synthesizing 2-[4-[(2,3,4-TRIMETHOXYPHENYL)METHYL] PIPERAZIN-1-YL]ETHYL PYRIDINE-3-CARBOXYLATEOct 8, 2024 · US 12,110,275Granted
- Methods Of Treating Heart Failure With Hibernating Myocardium Using Modified Forms Of TrimetazidineSep 3, 2024 · US 12,076,318Granted
- Crystal Forms Of 2-[4-[(2,3,4-TRIMETHOXYPHENYL)METHYL]PIPERAZIN-1-YL]ETHYL PYRIDINE-3-CARBOXYLATEAug 20, 2024 · US 12,065,410Granted
- Methods Of Treating Heart Failure With Reduced Ejection Fraction Using Modified Forms Of TrimetazidineJul 25, 2024 · Application 18624508Pending
- Methods Of Treating Heart Failure With Reduced Ejection Fraction Using Modified Forms Of TrimetazidineApr 30, 2024 · US 11,969,422Granted
- Combination TherapiesMar 14, 2024 · Application 18269820Pending
- Methods Of Treating Kidney Conditions Using Modified Forms Of TrimetazidineJan 30, 2024 · US 11,883,396Granted
- Compositions And Methods For Increasing Efficiency Of Cardiac MetabolismDec 19, 2023 · US 11,844,840Granted
- Methods Of Treating Heart Failure With Preserved Ejection Fraction Using Modified Forms Of TrimetazidineOct 24, 2023 · US 11,793,807Granted
- Methods Of Synthesizing 2-[4-[(2,3,4-TRIMETHOXYPHENYL)METHYL]PIPERAZIN-1-YL]ETHYL PYRIDINE-3-CARBOXYLATEOct 10, 2023 · US 11,780,811Granted
- Crystal Forms Of 2-[4-[(2,3,4-TRIMETHOXYPHENYL)METHYL]PIPERAZIN-1-YL]ETHYL PYRIDINE-3-CARBOXYLATESep 5, 2023 · US 11,746,090Granted
- Methods Of Treating Non-obstructive Hypertrophic Cardiomyopathy Using Modified Forms Of TrimetazidineAug 22, 2023 · US 11,730,733Granted
- Dosing Methods For Treatment Of Cardiovascular ConditionsJul 6, 2023 · Application 17922890Pending
- Crystal Forms Of 2-[4-[(2,3,4-TRIMETHOXYPHENYL)METHYL]PIPERAZIN-1-YL]ETHYL PYRIDINE-3-CARBOXYLATEDec 20, 2022 · US 11,530,184Granted
- Methods Of Altering Cardiac Remodeling Using Compounds That Promote Glucose OxidationAug 11, 2022 · Application 17614826Pending
- Combination Therapies That Include An Agent That Promotes Glucose Oxidation And An Inhibitor Of Pyruvate Dehydrogenase KinaseJul 21, 2022 · Application 17614810Pending
- Compositions And Methods For Increasing Efficiency Of Cardiac MetabolismJul 5, 2022 · US 11,376,330Granted
- Methods Of Treating Cancer Using Trimetazidine-based CompoundsJun 2, 2022 · Application 17439763Pending
- Modified Release Formulations Of Modified Forms Of TrimetazidineDec 30, 2021 · Application 17359714Pending
- Modified Release Formulations Of Modified Forms Of TrimetazidineDec 30, 2021 · Application 17359726Pending
- Tca Cycle Intermediates And Methods Of Use ThereofNov 11, 2021 · Application 17282581Pending
- Compositions And Methods For Treating And Preventing Leber's Hereditary Optic NeuropathyNov 11, 2021 · Application 17282587Pending
- Process For Producing Tca Cycle Intermediate ConjugatesOct 21, 2021 · Application 17226352Pending
Related companies, and why
- Xilio TherapeuticsSimilar federal contract value in Biotech · null in contracts
- EvozyneSimilar federal contract value in Biotech · null in contracts
- Ajax TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Nuvalent, Inc.Similar federal contract value in Biotech · null in contracts
- Electra TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Caribou BiosciencesSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .